MOSAIQUES DIAGNOSTICS GMBH

Their core work

Mosaiques Diagnostics is a Hannover-based SME specializing in clinical proteomics — the large-scale analysis of proteins in biological samples — to develop diagnostic biomarkers and identify therapeutic targets. Their core work spans urological cancers (prostate and bladder) and chronic kidney disease, where they use multi-omics profiling to support personalized treatment decisions. They serve as both a technology provider (proteomic analysis platforms) and a research partner in translational medicine, bridging the gap between molecular discovery and clinical application.

What they specialise in

How they've shifted over time

In their early H2020 phase (2014–2018), Mosaiques focused on biomarker discovery and molecular profiling — building protein-centric maps, validating preclinical platforms, and establishing their proteomic analysis capabilities across cancer and renal projects. From 2018 onward, the focus shifted decisively toward therapeutic applications: identifying drug targets, testing drug combinations, and applying systems biology and multi-omics integration to guide personalized treatment, especially in chronic kidney disease. The trajectory is clear — they moved from diagnostic discovery toward treatment-oriented precision medicine.

Mosaiques is moving from being a proteomics service provider toward becoming a precision medicine partner capable of guiding therapeutic decisions through integrated omics analysis, particularly in kidney disease.

How they like to work

Mosaiques operates as a balanced coordinator-participant, leading 6 of 13 projects — a high coordination rate for an SME, signaling strong project management capability and scientific credibility. Their 62 unique partners across 15 countries indicate a broad, non-exclusive network, suggesting they connect easily with new consortia rather than relying on a fixed circle. For potential partners, this means they are experienced at managing EU project logistics and bring an established pan-European network to any proposal.

With 62 unique consortium partners across 15 countries, Mosaiques has built a wide European network concentrated in biomedical and clinical research. Their partnerships span universities, hospitals, and research institutes across the EU, reflecting the translational nature of their work connecting lab proteomics to clinical settings.

What sets them apart

Mosaiques occupies a rare niche as a private SME with deep proteomics expertise that consistently coordinates EU research projects — most SMEs only participate. Their dual focus on urological cancers and chronic kidney disease, combined with proprietary proteomic analysis capabilities, makes them a go-to industry partner when consortia need clinical-grade molecular profiling. For anyone building a proposal in renal disease or urological oncology, they bring both the technology platform and a proven track record of EU project delivery.

Highlights from their portfolio

• DC-ren
  Largest single EC contribution (€701,050), focused on drug combinations for diabetic kidney disease — represents their strategic shift toward therapeutic applications.
• PROCEED
  Coordinator role combining proteomics with systems biology for CKD therapy — a flagship project linking their core technology to clinical treatment targets.
• ReDrugBC
  Their most recent coordinated project, applying drug repurposing to bladder cancer — shows expansion from diagnostics into therapeutic strategy.